

HEALTHCARE MONTHLY

MARCH 2023

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma Healthcare Services Life Sciences / Diagnostics Medical Devices



RGET ACQUIROR

ACQUISITION SYNOPSIS





- Biotage AB (STO:BIOT) has reached an agreement to acquire Astrea Bioseparations Ltd., a subsidiary of Gamma Biosciences, LP, which is a
 portfolio company of KKR & Co. Inc. (NYS:KKR)
- Astrea Bioseparations provides process chromatography solutions including columns, resins and nanofiber purification technology for life sciences and other industries
- Biotage, based in Sweden, develops and supplies instruments and consumables for separation used in organic, analytical and industrial applications
- Total Consideration: \$215 million, 7.7x 2022 Revenue, 59.1x 2022 EBITDA





- · CVS Health Corp. (NYSE:CVS) has reached a definitive agreement to acquire Oak Street Health LLC (NYSE:OSH)
- · Oak Street Health is a network of value-based primary care centers for adults on Medicare, operating over 160 medical centers across 21 states
- CVS Health is a leading health solutions company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider
- Total Consideration: \$9.8 billion in cash, 5.3x 2022 Revenue
- Per share price represents a premium of $\sim 50\%$





- Globus Medical, Inc. (NYSE:GMED) has reached a definitive agreement to acquire NuVasive, Inc. (NASDAQ:NUVA)
- NuVasive develops, manufactures and distributes medical devices and provides procedures for minimally invasive spinal surgery, including software systems for surgical planning and monitoring, access instruments and implantable hardware
- Globus Medical develops, manufactures and distributes musculoskeletal device solutions
- Total Consideration: \$3.0 billion in stock, 3.2x 2022 Revenue, 17.2x 2022 EBITDA
- Per share price represents a premium of ~26%






- · Abbott Laboratories (NYSE:ABT) has reached a definitive agreement to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII)
- Cardiovascular Systems is a medical device company that develops and commercializes solutions for treating peripheral and coronary artery disease
- Abbott Laboratories is a global healthcare leader with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines
- Total Consideration: \$745 million, 3.1x 2022 Revenue
- Per share price represents a premium of ~50%




HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)	MEI Pharma, Inc. (NASDAQ:MEIP)	Infinity Pharmaceuticals is a clinical-stage biotechnology company developing eganelisib, an oral, immuno-oncology macrophage reprogramming drug candidate Total Consideration: All-stock transaction (MEI Pharma shareholders are expected to own ~58% and pre-merger Infinity shareholders are expected to own ~42% of the outstanding equity of the combined company)
DMK Pharmaceuticals, Corp.	Adamis Pharmaceuticals Corp. (NASDAQ:ADMP)	DMK Pharmaceuticals develops treatments for central nervous disorders, including opioid use disorder, chronic pain, Parkinson's, depression and bladder problems
CRB-701 rights from CSPC Megalith Biopharmaceutical Co., Ltd. (CSPC Pharmaceutical Group (HKEX:01093)	Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)	CRB-701 is a novel clinical-stage antibody drug conjugate targeting Nectin-4 expressing tumors, with clinical development underway focusing on urothelial cancer Total Consideration: \$692 million, consisting of \$75 million upfront and \$685 million in earnout
Target	Acquiror	Life Sci / Diagnostics Transactions
Target Streck LLC	Acquiror Madison Industrie	Streck develops and manufactures products
		Streck develops and manufactures products addressing hematology, immunology, molecular diagnostics, cell stabilization and infectious diseases

Selected TM Capital Healthcare Experience









TM Capital's Healthcare Industry Contacts

(Ampersand

Capital Partners)



Innovations

James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com



Steve Hunter

Managing Director, Sponsor Coverage
shunter@tmcapital.com
404.995.6232



invasive generator, vascular compression system,

intra-aortic balloon pump, in-vitro diagnostics

equipment and more

Paul Smolevitz
Managing Director
smolevitz@tmcapital.com

